论文部分内容阅读
目的评价重组人血管内皮抑制度(恩度)联合化疗治疗晚期非小细胞肺癌的疗效和不良反应。方法 121例晚期非小细胞肺癌患者,按随机数字表法分成两组,其中58例恩度联合化疗治疗(试验组);63例仅接受化疗(对照组)。观察两组的近期总有效率、临床获益率和疾病进展时间。结果试验组总有效率37.93%(22/58),对照组为19.05%(12/63),两组比较差异有统计学意义(P<0.05);试验组临床获益率为81.03%(47/58),对照组为63.49%(40/63),两组比较差异有统计学意义(P<0.05);试验组的中位疾病进展时间为7.9个月,对照组为6.3个月(P<0.05)。试验组每个周期的药物不良反应发生率与对照组发生率的比较差异无统计学意义(P>0.05)。结论恩度联合化疗治疗晚期非小细胞肺癌临床疗效显著,可延长疾病进展时间,耐受性好,值得临床推广应用。
Objective To evaluate the efficacy and adverse reactions of recombinant human vascular endothelium inhibition (Endo) combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods One hundred and twelve patients with advanced non-small cell lung cancer were divided into two groups according to the random number table. Among them, 58 patients were enrolled in combination with chemotherapy (experimental group) and 63 patients received chemotherapy alone (control group). The two groups were observed the recent total effective rate, clinical benefit rate and disease progression time. Results The total effective rate was 37.93% (22/58) in the trial group and 19.05% (12/63) in the control group, with a significant difference between the two groups (P <0.05). The clinical benefit rate in the trial group was 81.03% (47 / 58 in the control group and 63.49% (40/63) in the control group, with a significant difference between the two groups (P <0.05). The median disease progression time was 7.9 months in the experimental group and 6.3 months in the control group (P <0.05). There was no significant difference in the incidence of adverse drug reaction between each experimental group and the control group (P> 0.05). Conclusion Endood combined with chemotherapy for advanced non-small cell lung cancer has significant clinical efficacy, which can prolong the progress of the disease and is well tolerated and worthy of clinical application.